Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Inovio Pharmaceuticals Inc
INO
Healthcare
Biotechnology
Inovio Pharmaceuticals, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing deoxyribonucleic acid (DNA) medicines to help treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines pipeline include INO-3107 for HPV-related recurrent respiratory papillomatosis (RRP...
); INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma, or OPSCC; VGX-3100 for the treatment of Anal or Perianal HSIL; INO-5401 for the treatment of Glioblastoma Multiforme (GBM), and INO-5401 for the Treatment of Glioblastoma Multiforme (GBM). Its lead candidate is INO-3107 for the treatment of RRP, a rare and debilitating disease of the respiratory tract caused by HPV infection. Its DNA medicines platform consists of DNA plasmids and its CELLECTRA devices, which are used to deliver the DNA plasmids into the cell. Its CELLECTRA device portfolio consists of two models.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:INO)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(229)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Aug 09, 2024 8:47pm
Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcrip
Just In: $INO Inovio Pharmaceuticals (INO) Q2 2024 Earnings Call Transcript2024-08-09 02:30:19 ET Image source: The Motley Fool. Inovio Pharmaceuticals (NASDAQ: INO) Q2 2024 Earnings Call Aug 08, 2024
...more
(229)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jul 11, 2024 12:30pm
INO-3107 Awarded the Innovation Passport Designation Under U
Just In: $INO INO-3107 Awarded the Innovation Passport Designation Under U.K. Government's Innovative Licensing and Access PathwayINO-3107 Awarded the Innovation Passport Designation Under U.K
...more
(229)
•••
whytestocks
X
View Profile
View Bullboard History
Post by
whytestocks
on Jan 24, 2024 8:30pm
INO announced stock split 1-12
BREAKING NEWS: $INO INO announced stock split 1-122024-01-24 08:02:09 ET Inovio Pharmaceuticals Inc (INO) announced stock split at a ratio of 1-for-12 on 2024-01-25 ... Full story available on
...more
(2)
•••
JayDestura
X
View Profile
View Bullboard History
Post by
JayDestura
on Apr 13, 2023 2:45am
Kevin Harrington Discusses FSD Pharma
I believe this new product will aid society in reducing the
...more
(2)
•••
JayDestura
X
View Profile
View Bullboard History
Post by
JayDestura
on Jul 13, 2022 11:58pm
FSD Pharma Subsidiary Lucid Psycheceuticals Files for Patent
(2)
•••
JayDestura
X
View Profile
View Bullboard History
Post by
JayDestura
on Jun 03, 2022 3:49am
FSD Will Proceed with Phase2 of FSD-201 Soon After Clearance
FSD Pharma ready to proceed with Phase 2 clinical trial of FSD
...more
(2)
•••
JayDestura
X
View Profile
View Bullboard History
Post by
JayDestura
on Jun 01, 2022 11:10pm
FSD Pharma Files Investigational New Drug Application “IND”
(2)
•••
JayDestura
X
View Profile
View Bullboard History
Post by
JayDestura
on May 10, 2022 11:18pm
FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets
(2)
•••
JayDestura
X
View Profile
View Bullboard History
Post by
JayDestura
on May 03, 2022 2:10am
Lucid-MS for Multiple Sclerosis Treatment
(2)
•••
JayDestura
X
View Profile
View Bullboard History
Post by
JayDestura
on Apr 25, 2022 3:16am
"Julia Levy Award" Recipient David Allan and Dr. John McGraw
(2)
•••
JayDestura
X
View Profile
View Bullboard History
Post by
JayDestura
on Apr 19, 2022 12:29am
FSD Pharma Inc: Lucid MS Video
FSD Pharma is delighted to announce pre-clinical findings
...more
(2)
•••
JayDestura
X
View Profile
View Bullboard History
Post by
JayDestura
on Apr 09, 2022 12:05am
FSD: Cancellation of Certain Shares Issued to Former CEO
FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A)
...more
(2)
•••
JayDestura
X
View Profile
View Bullboard History
Post by
JayDestura
on Apr 07, 2022 1:24am
FSD Pharma Issues Corporate Updates
FSD Pharma Issues Corporate Updates TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a life sciences holding company dedicated to
...more
(2)
•••
JayDestura
X
View Profile
View Bullboard History
Post by
JayDestura
on Apr 05, 2022 11:45pm
iMining: First Hospital Foundation in Decentraland Metaverse
iMining Enters into Agreement for the First-Ever Hospital Foundation to Be Launched in the Decentraland Metaverse Vancouver, British Columbia--(Newsfile Corp.) - iMining Technologies Inc
...more
(4)
•••
AviseAnalytics
X
View Profile
View Bullboard History
Post by
AviseAnalytics
on Mar 04, 2022 7:43am
INOVIO PHARMACEUTICALS: A LONG SHOT INVESTMENT!
$INO Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced that it is pausing enrolment for an ongoing late-stage study evaluating its lead COVID-19 vaccine candidate INO-4800, as labs tests show
...more
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >